Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 28, 2018
Event: Entry into a Material Definitive Agreement to acquire Adapt Pharma Limited ("Adapt"), an Irish private company specializing in NARCAN® (naloxone hydrochloride) Nasal Spray and opioid overdose treatments.
Key Financial Metrics and Transaction Structure
Total Consideration: Up to $735 million.
Upfront Payment: $635 million, comprised of:
- $575 million in cash.
- $60 million in Emergent common stock (subject to adjustment based on volume-weighted average price).
Milestone Payments: Up to $100 million in cash contingent on sales thresholds through 2022.
- First earn-out: Up to $50 million if net sales exceed thresholds for the period Jan 1, 2018 – Dec 31, 2019.
- Second earn-out: Up to $50 million if net sales exceed thresholds in any single calendar year ending on or prior to Dec 31, 2022.
Financing Arrangement: Emergent secured a commitment from Wells Fargo Bank for:
- $450 million incremental term loan.
- $150 million increase to the existing revolving credit facility (totaling $350 million).
- Proceeds from debt financing and cash on hand will fund the cash purchase price.
Other Financial Data: The filing text does not provide current revenue, profit, cash flow, margins, or existing debt levels for Emergent BioSolutions Inc. outside of the new financing commitments.
Material Changes and Conditions
Acquisition Status: Emergent will own 100% of Adapt's equity interests upon closing. The transaction is subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period.
Adjustments: The cash consideration is subject to adjustment based on Adapt's outstanding indebtedness, cash, working capital, manufacturing capital expenditures, and transaction expenses at closing. The stock consideration is subject to adjustment based on third-party payments and share price.
Equity Issuance: The common stock issued as consideration will be sold in a private placement under Section 4(a)(2) of the Securities Act. Sellers (Seamus Mulligan and affiliated entities) agreed to a two-year lock-up on these shares.
Outlook, Risks, and Management Commentary
Strategic Rationale: The acquisition expands Emergent's portfolio to include NARCAN® Nasal Spray and a development pipeline for new opioid overdose treatments.
Financing Risks: The debt financing is contingent on several conditions, including the absence of a "Company Material Adverse Effect," no events of default under the existing Credit Agreement, and the consummation of the acquisition prior to or concurrently with funding.
Regulatory Risks: Completion requires regulatory filings and antitrust clearance. The agreement prohibits Adapt from entering other material business combinations prior to closing.
Investor Verification Checklist
- Verify the final purchase price adjustments regarding Adapt's working capital and indebtedness at closing.
- Confirm the exact number of Emergent shares to be issued based on the volume-weighted average price prior to closing.
- Monitor the status of the Hart-Scott-Rodino Antitrust waiting period and other regulatory approvals.
- Review the full text of the Share Purchase Agreement and Commitment Letter (Exhibits 10.1 and 99.1) for specific covenants and termination rights.
- Assess the impact of the new $450 million term loan and increased leverage on Emergent's future debt service obligations.